THAR — Tharimmune Inc.
NASDAQ · Healthcare · Biotechnology
Tharimmune Inc. (THAR) is a biotechnology company listed on NASDAQ. It is led by Mark Wendland, based in 34 Shrewsbury Avenue, Red Bank, NJ, United States, 07701, with about 2 employees. Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
Net income was -$2.1M. THAR currently screens at market cap $187.4M.
Use this THAR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the THAR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the THAR SEC filings page. Lician reads the product cache first so this HTML stays unique to Tharimmune Inc. even when a live quote feed is slow.
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
THAR Key Statistics
Market Cap
$187.37M
P/B Ratio
0.50
EPS
-$9.41
Revenue
$0.00
Net Income
-$12.20M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
THAR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.20M | -$9.32M | -$8.47M | -$2.21M |
| EPS (Diluted) | -$9.41 | -$107.02 | -$18.72 | $0.00 |
Total Assets
$3.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.56M
Operating Cash Flow
-$10.90M
Free Cash Flow
$0.00
Tharimmune Inc. Company Information
- CEO & Chairman of the Board
- Mark Wendland
- Headquarters
- 34 Shrewsbury Avenue, Red Bank, NJ, United States, 07701
- Website
- www.tharimmune.com
- Phone
- 732 889 3111
- IPO / Founded
- 2022-01-12
- Sector
- Healthcare
- Industry
- Biotechnology